M&A Deal Summary |
|
|---|---|
| Date | 2025-05-06 |
| Target | Lantheus Medical Imaging - SPECT Business |
| Sector | Life Science |
| Buyer(s) | SHINE Technologies |
| Sellers(s) | Lantheus Medical Imaging |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2010 |
| Sector | Life Science |
SHINE Technologies engages in developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy. SHINE Technologies was founded in 2010 and is based in Janesville, Wisconsin.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1956 |
| Sector | Medical Products |
| Employees | 808 |
| Revenue | 1.5B USD (2024) |
Lantheus Medical Imaging is a supplier of radiopharmaceuticals and contrast agents for nuclear and ultrasound-based cardiovascular diagnostic imaging procedures. Lantheus Medical Imaging was founded in 1956 and is based in Bedford, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 2 of 2 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-01-28 |
Evergreen Theragnostics
Springfield, New Jersey, United States Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen Theragnostics was founded in 2019 and is based in Springfield, New Jersey. |
Buy | $250M |
